This is a summary of the European public assessment report (EPAR) for Unituxin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is
For practical information about using Unituxin, patients should read the package leaflet or contact their doctor or pharmacist.
Unituxin is a cancer medicine used to treat neuroblastoma, a nerve cell cancer, in children aged 12
months to 17 years.
Unituxin is used to treatMedicinalchildren with
chance of returning. Children treated with Unituxin will first have responded to chemotherapy and then received an additional treatment to clear out their bone marrow (myeloablative therapy) and a stem- cell transplantation.
Unituxin is given in combination with 3 other medicines:
Because the number of patients with neuroblastoma is low, the disease is considered ‘rare’, and Unituxin was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 21 June 2011.
Unituxin contains the active substance dinutuximab.
How is Unituxin used?
Unituxin is given as an infusion (drip) into a vein. The daily dose depends on the child’s body surface area, and infusions are given over 10 hours. The patient also receives 3 other medicines: isotretinoin,
- Dinutuximab beta apeiron - dinutuximab beta
Prescription drugs listed. Substance: "Dinutuximab"
Because of the risk of severe allergic reactions with Unituxin, equipment and staff should be immediately available to resuscitate the patient if reactions occur. Patients should also be given an antihistamine medicine before the start of each Unituxin infusion to reduce the risk of a reaction.
Because pain is a common side of Unituxin treatment, patients are also given pain killers.
Unituxin is only for hospital use and treatment should be supervised by a doctor experienced in cancer treatments. The medicine can only be obtained with a prescription.
How does Unituxin work?
The active substance in Unituxin, dinutuximab, is a monoclonal antibody, designed to recognise and
attach to a substance present at high levels in neuroblastoma cancer cells known as ganglioside GD2. When dinutuximab attaches to the gangliosides on neuroblastoma cells, it marks the cells out as
A main study conducted in 230 patients with
targets for the immune system (the body’s natural defences), which then attack them. In this way, the medicine can help clear out cancer cells remaining in the body following other treatments.
What benefits of Unituxin have been shown in studies?
urticaria (hives), capillary leak syndromeproduct(a condition whereby fluid leaks from the blood vessels causing swelling and fall in blood pressure), anaemia (low red blood cell counts), low platelet counts,
The most common side effects with Unituxin (seen in more than 30% of patients) are: pain affecting
any part of the body, hypotension (low bl pressure), hypersensitivity (allergic reactions), fever,
low sodium and potassiumMedicinallevels, r ised liver enzymes and low levels of white blood cells. For the full list of all side effects and restri tions, see the package leaflet.
Why is Unituxin approved?
Although side effects with Unituxin can be severe, and medication is required to prevent allergic reactions and pain, the medicine’s risks are considered acceptable given the severity of the disease. The number of patients who have to stop treatment because of side effects appears low and the side effects can be managed with appropriate measures.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) therefore concluded that Unituxin’s benefits are greater than its risks and recommended that it be approved for use in the EU.
What measures are being taken to ensure the safe and effective use of Unituxin?
A risk management plan has been developed to ensure that Unituxin is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Unituxin, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, the company that markets Unituxin will carry out two studies to get more information about the safety of the medicine, including its
Further information can be found in the summary of the risk management plan.
Other information about Unituxin
The European Commission granted a marketing authorisation valid throughout the European Union for
Unituxin on 14 August 2015.
information about treatment with Unituxin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
The full EPAR and risk management plan summary for Unituxin canauthorisedbe found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more
The summary of the opinion of the Committee for Orphan Medicinal Products for Unituxin can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.